Develops point-of-care diagnostic devices that use biomarker analysis and advanced algorithms for the ultra-sensitive detection of infectious diseases and cancers. These systems enable rapid, low-cost testing at the site of care, facilitating early diagnosis and timely treatment to improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods for detecting infectious diseases and cancers often require laboratory analysis, resulting in delayed diagnosis and treatment initiation. The need for specialized equipment and trained personnel limits accessibility, particularly in point-of-care settings and resource-constrained environments.
Solution
Labionyx develops point-of-care diagnostic devices that enable rapid and ultra-sensitive detection of infectious diseases and cancers. Their technology utilizes biomarker analysis and advanced algorithms to provide precise results at the point of need, facilitating timely diagnosis and treatment decisions. The devices are designed for user-friendly operation and low-cost testing, making them suitable for various healthcare settings. By enabling early detection and monitoring of diseases, Labionyx aims to improve patient outcomes through proactive healthcare solutions.
Target Audience
The primary target audience includes healthcare providers, hospitals, and clinics seeking rapid and accurate diagnostic tools for infectious diseases and cancers at the point of care.
Features
- Point-of-care testing for rapid results
- Ultra-sensitive detection of infectious diseases and cancers
- Biomarker analysis for precise diagnostics
- Advanced algorithms for accurate interpretation of results
- User-friendly operation for ease of use
- Low-cost testing for increased accessibility